KCNQ1DN therefore suppresses RCC in vitro and in vivo through repressing c-Myc oncogene transcription and expression, and KCNQ1DN down-regulation is a marker for poor patient prognosis and a therapeutic target (Table 2). This evidence concerns the gene MYC and renal cell carcinoma.